• Chat
  • Dashboard
    • Feedback
    Log inGet Started

    Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar - CNBC

    AI Summary1 min read

    TL;DR

    Eli Lilly exceeded earnings estimates and raised its 2025 guidance, driven by strong sales of Zepbound and Mounjaro weight loss drugs, boosting its stock price.

    Tags

    Eli LillyZepboundMounjaroearningsguidance
    1. Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar  CNBC
    2. Eli Lilly Stock Rises on Earnings and Boost to Guidance  Barron's
    3. Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance  Yahoo Finance
    4. Lilly Raises Guidance on Strength of Weight Loss, Obesity Drugs  Bloomberg.com
    5. Eli Lilly stock pops on raised full-year outlook (LLY:NYSE)  Seeking Alpha

    Thursday, October 30, 2025 10:52 AM

    Visit Website
    website-logo

    Top stories - Google News

    Google News

    channel icon
    Related Articles

    AI spending is helping prop up the economy. Now it’s getting stronger. - The Washington Post

    Oct 30, 2025

    Peacock Posts $217 Million Loss as Subscribers Remain Unchanged at 41 Million - The Hollywood Reporter

    Oct 30, 2025

    The New ‘Stranger Things’ Season 5 Trailer Brings the Final Battle to Hawkins - Gizmodo

    Oct 30, 2025

    Hurricane Melissa leaves trail of destruction across Caribbean - BBC

    Oct 30, 2025
    xgithub
    logo

    Copyright © 2022-2025 - Aetos.AI